# EDGAR Filing Document

**Accession Number:** 0001861560
**File Stem:** 0001193125-26-264042
**Filing Date:** 2026-6
**Character Count:** 66131
**Document Hash:** cd06d30f566e6aed78bdabb6592e99fd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-264042.hdr.sgml**: 20260609

**ACCESSION NUMBER**: 0001193125-26-264042

**CONFORMED SUBMISSION TYPE**: SC14D9C

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20260609

**DATE AS OF CHANGE**: 20260609

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nuvalent, Inc.
- **CENTRAL INDEX KEY:** 0001861560
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC14D9C
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92743
- **FILM NUMBER:** 261077165

**BUSINESS ADDRESS:**
- **STREET 1:** ONE BROADWAY, 14TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 508-446-2272

**MAIL ADDRESS:**
- **STREET 1:** ONE BROADWAY, 14TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nuvalent, Inc.
- **CENTRAL INDEX KEY:** 0001861560
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC14D9C

**BUSINESS ADDRESS:**
- **STREET 1:** ONE BROADWAY, 14TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 508-446-2272

**MAIL ADDRESS:**
- **STREET 1:** ONE BROADWAY, 14TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14D-9** 

**SOLICITATION/RECOMMENDATION STATEMENT** 

**PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934** 

## NUVALENT, INC.
**(Name of Subject Company)** 

**(Name of Person(s) Filing Statement)** 

**Class A Common Stock, $0.0001 par value per share** 

**Class B Common Stock, $0.0001 par value per share** 

**(Title of Class of Securities)** 

**670703107** 

**(CUSIP Number of Class A Common Stock)** 

**James R. Porter** 

**Chief Executive Officer** 

**Nuvalent, Inc.** 

**One Broadway, 14th Floor,** 

**Cambridge, Massachusetts 02142** 

**(857) 357-7000** 

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Person(s) Filing Statement)** 

***With a copy to:***

**Emily Oldshue** 

**Nicholas Roper** 

**Ropes & Gray LLP** 

**800 Boylston Street, Prudential Tower** 

**Boston, MA 02199** 

**(617) 951-7000** 

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a
tender offer.

------

This Schedule 14D-9 filing consists of the following communications related to the proposed acquisition of Nuvalent, Inc., a Delaware corporation (the "Company" or "Nuvalent"), pursuant to the terms of the Agreement and Plan of Merger, dated as of June 9, 2026 (the "Merger Agreement"), by and among the Company, GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and, solely for purposes of Section 9.14 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"):

1) Exhibit 99.1: Email from James R. Porter, Chief Executive Officer of the Company, sent to employees, dated June 9, 2026.

2) Exhibit 99.2: Employee FAQ, dated June 9, 2026.

3) Exhibit 99.3: Investor FAQ, dated June 9, 2026.

4) Exhibit 99.4: Partner Letter, dated June 9, 2026.

The items listed above were first used or made available on June 9, 2026.

The information set forth under Items 1.01, 7.01 and 9.01 of the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") by the Company on June 9, 2026 (including all exhibits attached thereto) is incorporated herein by reference.

**Additional Information and Where to Find It** 

Purchaser will commence a tender offer for the outstanding shares of common stock of Nuvalent, but such offer has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Nuvalent, nor is it a substitute for the tender offer materials that Ultimate Parent, Parent, and Purchaser will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Ultimate Parent, Parent and Purchaser will file a tender offer statement on Schedule TO, and Nuvalent will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. The tender offer statement on Schedule TO (including an offer to purchase, a related letter of transmittal, and other tender offer documents) and the Solicitation/Recommendation Statement will contain important information. HOLDERS OF SHARES OF NUVALENT ARE URGED TO READ THESE DOCUMENTS WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT NUVALENT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The offer to purchase, the related letter of transmittal, and other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all Nuvalent stockholders at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement also will be made available for free at the SEC's web site at www.sec.gov. Additional copies may be obtained for free on Nuvalent's website, www.nuvalent.com.

In addition to the Solicitation/Recommendation Statement, Nuvalent files annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by Nuvalent with the SEC for free at the SEC's website at www.sec.gov.

------

**Cautionary Statement Regarding Forward-Looking Statements** 

This Schedule 14D-9C includes forward-looking statements that are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. All statements, other than statements of historical fact, are generally forward-looking statements, including all statements regarding the intent, belief, or expectations of Nuvalent and its management. These forward-looking statements typically can be identified by words such as "believe," "expect," "estimate," "predict," "target," "potential," "likely," "continue," "ongoing," "could," "should," "intend," "may," "might," "plan," "seek," "anticipate," "project" and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the proposed transaction, similar transactions, prospective performance, future plans, events, expectations, performance, objectives, opportunities, and the outlook for Nuvalent's business; the anticipated timing of potential regulatory approval for Nuvalent's product candidates; the timing of and receipt of filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties; accordingly, investors are cautioned not to place undue reliance on forward-looking statements. Actual results may differ materially due to several factors. Factors that could cause future results to differ materially include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Nuvalent's stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change, or other circumstance that could give rise to the termination of the merger agreement, including circumstances requiring Nuvalent to pay a termination fee pursuant to the merger agreement; the ability of the parties to consummate the proposed transaction on a timely basis or at all; the effects of the transaction (or the announcement or pendency thereof) on relationships with associates, vendors, manufacturers, suppliers, employees (including the risks relating to the ability to retain or hire key personnel), other business partners, or governmental entities or patient groups; transaction costs; the risk that the transaction will divert management's attention from Nuvalent's ongoing business operations or otherwise disrupts Nuvalent's ongoing business operations; changes in Nuvalent's businesses during the period before any closing; certain restrictions during the pendency of the proposed transaction that may impact Nuvalent's ability to pursue certain business opportunities or strategic transactions; risks associated with litigation; risks unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies and clinical trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials; the risk that data from Nuvalent's clinical trials may not be sufficient to support registration and that Nuvalent may be required to conduct one or more additional studies or trials prior to seeking registration of zidesamtinib or neladalkib; risks that Nuvalent may not achieve the goals and milestones set forth in its OnTarget 2026 operating plan; the occurrence of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent's clinical trials, strategy, and future operations, including the ARROS-1, ALKOVE-1, ALKAZAR and HEROEX-1 trials; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and risks related to obtaining, maintaining, and protecting Nuvalent's intellectual property; and other factors as set forth in Nuvalent's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the SEC on May 7, 2026, and other reports filed with the SEC. The forward-looking statements set forth herein speak only as of the date hereof. Nuvalent undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by applicable law.

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | [Email from James R. Porter, Chief Executive Officer of the Company, sent to employees, dated June 9, 2026.](d130887dex991.htm) |
| 99.2 | [Employee FAQ, dated June 9, 2026.](d130887dex992.htm) |
| 99.3 | [Investor FAQ, dated June 9, 2026.](d130887dex993.htm) |
| 99.4 | [Partner Letter, dated June 9, 2026.](d130887dex994.htm) |

---

## Exhibit 99.1

**Exhibit 99.1** 

**Nuvalent Transaction All-Employee Note** 

**To**: All Nuvalent Employees

**From**: James Porter

**Subject**: An Exciting New Chapter

**Date**: June 9, 2026

Hello Team,

Earlier this morning, we announced that Nuvalent has agreed to be acquired by GSK. This transaction is a landmark achievement for our company that will help realize the full potential of our pipeline and make a meaningful difference in the lives of patients living with cancer. You can read our press release on the announcement <u>here</u>.

GSK is one of the largest pharmaceutical companies in the world with a proven track record of successfully bringing a wide array of breakthrough therapies to market. As part of GSK, we expect that their infrastructure and expertise will enable successful commercialization of our products globally to realize the full potential of zidesamtinib and neladalkib, as well as continued exploration of the future potential of the rest of our pipeline. Most importantly, the GSK team recognizes the value of our talented team, understands the significance of the relationships we've built with the patient communities and treating physicians, and shares our vision for practice-changing innovation.

While we are excited about this transaction, we are only at the beginning of the process. Looking ahead, the transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including the tender of a majority of the shares of our Class A common stock by our stockholders in the tender offer described in the press release and expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act in the U.S. Until then, GSK and Nuvalent will continue to operate as separate companies. Our daily operations and performance goals remain unchanged. Everyone should stay focused on delivering on our commitment of delivering new, potentially best-in-class medicines to patients as quickly as possible.

I recognize that you all may have some questions about the path forward. An invitation will be sent out shortly for an All-Hands Meeting to be held virtually today at 11:00 am ET. I encourage you to attend if possible. In addition, Sarah will be scheduling optional group check-ins throughout the day for anyone who would like to connect in a smaller group setting. I and certain other LT members will be in the office if you'd like to join the town hall or your group check-in in person.

Our leadership team will be working with each of their departments to align on a coordinated communications plan for our external partners such as vendors, clinical trial investigators, and patient advocacy groups. Should you receive questions about this announcement from investors, the media or other third parties, please direct them to inquiries@nuvalent.com.

As always, thank you for your dedication and commitment. What we do each day here at Nuvalent is deeply important, and I am proud of all that we have accomplished. I'm excited for what's to come.

With sincere appreciation,

Jim

------

**Additional Information and Where to Find It** 

The tender offer for the outstanding shares of common stock of Nuvalent has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Nuvalent, nor is it a substitute for the tender offer materials that GSK and its acquisition subsidiaries will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, GSK and its acquisition subsidiaries will file a tender offer statement on Schedule TO, and Nuvalent will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. The tender offer statement on Schedule TO (including an offer to purchase, a related letter of transmittal, and other tender offer documents) and the Solicitation/Recommendation Statement will contain important information. HOLDERS OF SHARES OF NUVALENT ARE URGED TO READ THESE DOCUMENTS WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT NUVALENT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The offer to purchase, the related letter of transmittal, and other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all Nuvalent stockholders at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement also will be made available for free at the SEC's web site at www.sec.gov. Additional copies may be obtained for free on Nuvalent's website, <u>www.nuvalent.com</u>.

**Cautionary Statement Regarding Forward-Looking Statements** 

This communication includes forward-looking statements that are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. All statements, other than statements of historical fact, are generally forward-looking statements, including all statements regarding the intent, belief, or expectations of Nuvalent and its management. These forward-looking statements typically can be identified by words such as "believe," "expect," "estimate," "predict," "target," "potential," "likely," "continue," "ongoing," "could," "should," "intend," "may," "might," "plan," "seek," "anticipate," "project" and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the proposed transaction, similar transactions, prospective performance, future plans, events, expectations, performance, objectives, opportunities, and the outlook for Nuvalent's business; the anticipated timing of potential regulatory approval for Nuvalent's product candidates; the timing of and receipt of filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties; accordingly, investors are cautioned not to place undue reliance on forward-looking statements. Actual results may differ materially due to several factors. Factors that could cause future results to differ materially include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Nuvalent's stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change, or other circumstance that could give rise to the termination of the merger agreement, including circumstances requiring Nuvalent to pay a termination fee pursuant to the merger agreement; the ability of the parties to consummate the proposed transaction on a timely basis or at all; the effects of the transaction (or the announcement or pendency thereof) on relationships with associates, vendors, manufacturers, suppliers, employees (including the risks relating to the ability to retain

------

or hire key personnel), other business partners, or governmental entities or patient groups; transaction costs; the risk that the transaction will divert management's attention from Nuvalent's ongoing business operations or otherwise disrupts Nuvalent's ongoing business operations; changes in Nuvalent's businesses during the period before any closing; certain restrictions during the pendency of the proposed transaction that may impact Nuvalent's ability to pursue certain business opportunities or strategic transactions; risks associated with litigation; risks unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies and clinical trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials; the risk that data from Nuvalent's clinical trials may not be sufficient to support registration and that Nuvalent may be required to conduct one or more additional studies or trials prior to seeking registration of zidesamtinib or neladalkib; risks that Nuvalent may not achieve the goals and milestones set forth in its OnTarget 2026 operating plan; the occurrence of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent's clinical trials, strategy, and future operations, including the ARROS-1, ALKOVE-1, ALKAZAR and HEROEX-1 trials; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and risks related to obtaining, maintaining, and protecting Nuvalent's intellectual property; and other factors as set forth in Nuvalent's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the SEC on May 7, 2026, and other reports filed with the SEC. The forward-looking statements set forth herein speak only as of the date hereof. Nuvalent undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by applicable law.

## Exhibit 99.2

**Exhibit 99.2** 

**Nuvalent Transaction Employee FAQ** 

**1.** **Why is GSK acquiring Nuvalent? Why now?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• This team has generated a tremendous amount of positive momentum across all aspects of our business. Nuvalent is
an attractive opportunity that is anchored by two potential best-in-class lung programs with positive pivotal data and clear near-term paths to first FDA approvals, and
followed by an innovative early stage clinical and discovery portfolio.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our goal has always been to advance these therapies as quickly as possible for patients around the world. GSK is
one of the largest pharmaceutical companies in the world, with the infrastructure, resources, and expertise to successfully commercialize our products globally and realize the potential of our pipeline.

**2.** **Why is GSK the right partner for Nuvalent?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Nuvalent's mission is to build a sustainable company that can discover, develop, and deliver medicines for
patients with cancer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GSK has a proven track record of bringing a wide range of breakthrough therapies to market, including in oncology
where GSK is advancing a diverse and innovative pipeline.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We expect that GSK's infrastructure, resources, and expertise will help realize the full potential of
zidesamtinib and neladalkib, as well as explore the future potential of the rest of our pipeline.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are confident GSK is the right company to advance our work to make a meaningful impact for patients living
with cancer.

**3.** **Is GSK only interested in zidesamtinib and neladalkib? What about the rest of our pipeline?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The GSK team recognizes the value and potential of our discovery pipeline and this was an important factor in
GSK's decision to enter into this agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GSK has a leading position in oncology, and targeted therapies in particular.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We expect to learn more about GSK's development plans after the transaction closes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Until that time, we will continue to run our business in the ordinary course and execute on our commercial launch
readiness and R&D priorities.

**4.** **When is the transaction expected to close?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The transaction is expected to close in the third quarter of 2026, subject to receipt of customary regulatory
approvals and satisfaction of other conditions to the transaction, including the tender of a majority of the shares of our Class A common stock by our stockholders.

**5.** **What does this transaction mean for employees? Does this impact my day-to-day responsibilities?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• This transaction would not be possible without your dedication, effort, and contributions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The GSK team recognizes the value of our talented team, understands the significance of the relationships
we've built with the patient communities and treating physicians, and shares our vision for practice-changing innovation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our daily operations and performance goals remain unchanged. It is business as usual at Nuvalent, and everyone
should stay focused on delivering on our commitments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Until the transaction closes, GSK and Nuvalent will continue to operate as separate, independent companies.

------

**6.** **Will there be any layoffs as a result of the transaction?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The GSK team wants to ensure that our team is able to remain firmly focused on advancing our programs, and that
patients remain our number one priority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Please understand that this announcement is only the first step toward completing this transaction. After the
transaction closes, GSK will work closely with the Nuvalent leadership team to plan the next steps and looks forward to meeting and getting to know the talented employees at Nuvalent. While we don't have all of the specifics at this point,
we're committed to sharing more information as soon as we are able to do so.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In recognition of employee contributions and the importance of this team to the continued successful advancement
of all of our portfolio efforts, GSK has agreed to the full acceleration of our equity package.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GSK has also agreed to honor Nuvalent's severance programs and maintain severance benefits to employees
that are at least favorable to current plans and agreements during the 12-month period after the transaction closes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We expect many of our employees can benefit from expanded career opportunities afforded by a larger organization
after the close of the transaction.

**7.** **Will there be changes to compensation or benefits?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We will continue to operate under our current compensation and benefit programs through closing of the
transaction, and GSK has agreed to provide you the same base salary and cash incentive opportunities and equivalent benefits for 12 months thereafter during the course of employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We will keep you informed as we move forward.

**8.** **I own Nuvalent stock or stock options, RSUs or PSUs. What will happen to employee stock and incentive equity?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• All Nuvalent shareholders will receive $124.00 in cash per share of Class A or Class B common stock at
close of the transaction. For our employees, this includes shares purchased via our ESPP program, of which the final purchase date will be accelerated to a date prior to the closing of the transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GSK has agreed to the full acceleration of our employee equity package. This means that employees who have
Nuvalent stock options will be "cashed-out" at the close of the transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In simple terms, both vested and unvested stock options will be converted to a cash dollar amount equal to the
difference between the per-share deal price of $124.00 and the per share strike price of the option, multiplied by the number of shares subject to the options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As an example, an employee with 500 vested stock options and 500 unvested stock options with a strike price of
$24.00 per share will receive a cash payment of $100,000 at the close of the transaction ($124.00 - $24.00) \* (500 + 500) (calculated before any required withholdings).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Employees who hold RSUs and/or PSUs will receive a cash payment equal to $124.00 per RSU or PSU at closing,
regardless of whether an RSU or PSU is vested or unvested; all performance conditions for PSUs will be deemed satisfied in full as of closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash payments made to holders of equity awards with respect to their equity awards will generally be subject to
applicable withholding taxes and deductions. We recommend that employees seek the advice of their tax advisor with respect to any tax implications resulting from the treatment of equity awards at the closing of the transaction.

------

**9.** **Please explain what a tender offer means.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A wholly owned subsidiary of GSK will commence a tender offer to all of Nuvalent's stockholders offering to
acquire all outstanding shares of Nuvalent's common stock. The offer must remain open for at least 20 calendar days, and the offer period could be extended. If at least a majority of the outstanding shares of Nuvalent's Class A
Common Stock are tendered by stockholders in the offer, and subject to receipt of customary regulatory approvals and satisfaction of other conditions to the transaction, GSK's subsidiary will consummate the offer to acquire the tendered
shares. Promptly following the closing of the tender offer, GSK will acquire any remaining shares of Nuvalent through a second-step merger under Delaware law at the same price per share.

**10.** **Will employees need to relocate following closing of the transaction?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GSK is looking forward to meeting and getting to know the talented employees at Nuvalent once the proposed
transaction has closed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We will keep you informed as we learn more.

**11.** **What will the role of our leadership team be once the transaction closes?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• More information with respect to our leadership team will be determined as part of the integration planning
process in the coming weeks and months.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Jim and the rest of the leadership team are focused on a successful commercial launch, advancing our other
development priorities and closing the transaction, setting Nuvalent up for success as it enters its next chapter.

**12.** **What happens if someone didn't attend the town hall on June 9th? How will this info be communicated to them?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The townhall session was not recorded. Employees can reach out to [\*\*\*] with questions. This
is a new mailbox created to address all employee questions about the transaction.

**13.** **What should I do if I am contacted by outside parties about the transaction?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Please do not answer questions yourself or speculate about this transaction. It is imperative that we maintain
consistent, pre-approved messaging.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Should you receive questions about this announcement, from investors, the media or other third parties, please
direct them to [\*\*\*].

**14.** **When will I receive more information? Who can I go to if I have any questions?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We want to provide ample opportunity for all questions to be addressed after you have time to absorb this update.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Toward that end, Sarah will begin scheduling group check-ins with Jim to
be conducted this afternoon and all day tomorrow.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• You can also send questions to [\*\*\*]. This is a new mailbox we've created to ensure that
we're able to address all employee questions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• There are many decisions still to be made and details to be worked out, and we're committed to keeping you
informed as we move forward.

------

**Additional Information and Where to Find It** 

The tender offer for the outstanding shares of common stock of Nuvalent has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Nuvalent, nor is it a substitute for the tender offer materials that GSK and its acquisition subsidiaries will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, GSK and its acquisition subsidiaries will file a tender offer statement on Schedule TO, and Nuvalent will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. The tender offer statement on Schedule TO (including an offer to purchase, a related letter of transmittal, and other tender offer documents) and the Solicitation/Recommendation Statement will contain important information. HOLDERS OF SHARES OF NUVALENT ARE URGED TO READ THESE DOCUMENTS WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT NUVALENT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The offer to purchase, the related letter of transmittal, and other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all Nuvalent stockholders at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement also will be made available for free at the SEC's web site at www.sec.gov. Additional copies may be obtained for free on Nuvalent's website, www.nuvalent.com.

**Cautionary Statement Regarding Forward-Looking Statements** 

This communication includes forward-looking statements that are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. All statements, other than statements of historical fact, are generally forward-looking statements, including all statements regarding the intent, belief, or expectations of Nuvalent and its management. These forward-looking statements typically can be identified by words such as "believe," "expect," "estimate," "predict," "target," "potential," "likely," "continue," "ongoing," "could," "should," "intend," "may," "might," "plan," "seek," "anticipate," "project" and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the proposed transaction, similar transactions, prospective performance, future plans, events, expectations, performance, objectives, opportunities, and the outlook for Nuvalent's business; the anticipated timing of potential regulatory approval for Nuvalent's product candidates; the timing of and receipt of filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties; accordingly, investors are cautioned not to place undue reliance on forward-looking statements. Actual results may differ materially due to several factors. Factors that could cause future results to differ materially include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Nuvalent's stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change, or other circumstance that could give rise to the termination of the merger agreement, including circumstances requiring Nuvalent to pay a termination fee pursuant to the merger agreement; the ability of the parties to consummate the proposed transaction on a timely basis or at all; the effects of the transaction (or the announcement or pendency thereof) on relationships with associates, vendors, manufacturers, suppliers, employees (including the risks relating to the ability to retain or hire key personnel), other business partners, or governmental entities or patient groups; transaction costs; the risk that the transaction will divert management's attention from Nuvalent's ongoing business operations or otherwise disrupts Nuvalent's ongoing business operations; changes in Nuvalent's businesses during the period before any closing; certain restrictions during the pendency of the proposed transaction that may impact Nuvalent's ability to pursue certain business opportunities or strategic transactions; risks associated with litigation; risks unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies and clinical trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials; the risk that data from Nuvalent's clinical trials may not be sufficient to support registration and that Nuvalent may be required to conduct one or more additional studies or trials prior to seeking registration of zidesamtinib or neladalkib; risks that Nuvalent may not achieve the goals and milestones set forth in its OnTarget 2026 operating plan; the occurrence of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent's clinical trials, strategy, and future operations, including the ARROS-1, ALKOVE-1, ALKAZAR and HEROEX-1 trials; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and risks related to obtaining, maintaining, and protecting Nuvalent's intellectual property; and other factors as set forth in Nuvalent's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the SEC on May 7, 2026, and other reports filed with the SEC. The forward-looking statements set forth herein speak only as of the date hereof. Nuvalent undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by applicable law.

## Exhibit 99.3

**Exhibit 99.3** 

**Page 1 of 3** 

**Nuvalent Transaction: Investor / Analyst Q&A** 

***Background / Rationale***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.** **Why this transaction? Why now?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• This transaction follows a review by our Board to determine the most value-creating path for Nuvalent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Combining with GSK delivers a significant and certain cash value to our stockholders at a compelling premium
– and our Board unanimously determined this transaction was in their best interests.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Further, as we look to advance zidesamtinib and neladalkib, we are excited to join a company that shares our
mission and has the infrastructure, resources, and expertise that will enable successful commercialization globally and realize their full potential, as well as explore the future potential of the rest of our pipeline.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.** **How did this transaction come together? Who approached whom? How long have you been in discussions?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Nuvalent Board is always evaluating potential opportunities to create value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We've long respected GSK as a leader in our industry, and are confident that this transaction is in the
best interest of Nuvalent and our stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Additional details regarding this process will be available in our SEC filings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.** **How does the premium compare to other similar transactions in the industry?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are pleased to have reached agreement on this transaction, which delivers significant and certain value to
stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The purchase price represents a premium of approximately 40% to the closing price of Nuvalent's common
stock on June 8, 2026 and 26% to the 30-day VWAP of Nuvalent's common stock ended on June 8, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.** **Did you consider any other transactions? Did you try to negotiate a higher price?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Nuvalent Board considered a number of options to create value and unanimously determined the transaction with
GSK is in the best interests of the Company and our stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• This combination provides stockholders with significant and certain cash value, at a compelling premium of
approximately 40% to the closing price of Nuvalent's common stock on June 8, 2026 and 26% to the 30-day VWAP of Nuvalent's common stock ended on June 8, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Additional details regarding this process will be available in our SEC filings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.** **Did you consider a deal with a stock component?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Nuvalent Board considered a number of options to create value and unanimously determined this transaction
with GSK is in the best interest of the Company and our stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• This combination provides stockholders with significant and certain cash value, at a compelling premium of
approximately 40% to the closing price of Nuvalent's common stock on June 8, 2026 and 26% to the 30-day VWAP of Nuvalent's common stock ended on June 8, 2026.

------

**Page 2 of 3** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.** **Why not continue as a standalone company? Isn't there a lot of potential with zidesamtinib and neladalkib?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our Board is focused on pursuing the most value-creating path for Nuvalent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In line with this commitment, the Board considered a number of factors in its determination that this deal with
GSK was in the best interests of stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• These included the anticipated commercial launch of zidesamtinib, the need to continue to grow our company and
related risks of execution of our commercialization plans and the development of our other pipeline products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Ultimately, we are confident the deal with GSK is the best path forward as the transaction delivers significant
and certain cash value to our stockholders, while providing important access to GSK's infrastructure, resources, and expertise. This will enable successful commercialization of our products globally to realize the full potential of
zidesamtinib and neladalkib, as well as exploration of the future potential of the rest of our pipeline.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.** **Was Nuvalent's Board unanimous in approving this deal?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Yes. The transaction was unanimously approved by the Nuvalent Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.** **Does this sale signal a loss of confidence in your strategy or pipeline?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• No.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In fact, by partnering with GSK, Nuvalent's programs will benefit from the infrastructure, resources, and
expertise that will enable successful commercialization of our products globally to realize the full potential of zidesamtinib and neladalkib. It will also allow exploration of the future potential of the rest of our pipeline.

***Terms / Financials***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.** **What are the terms of the agreement?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GGSK will commence a tender offer to acquire all of the outstanding shares of Nuvalent for $124 per share
of common stock in an all-cash transaction (equal to an aggregate equity value of approximately $10.6 billion).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The purchase price represents a premium of approximately 40% to the closing price of Nuvalent's
common stock on June 8, 2026 and 26% to the 30-day VWAP of Nuvalent's common stock ended on June 8, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.** **Is there a go-shop provision?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• No.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11.** **Is there a break-up fee? If so, how much?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Yes. The break-up fee is approximately $350 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Additional details will be available in our SEC filings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12.** **What happens if another party comes in with a higher bid? Would GSK increase its offer?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We're not going to comment on hypotheticals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• What I can say is that we're focused on the transaction with GSK and are confident that it is in the best
interests of Nuvalent and our stockholders.

------

**Page 3 of 3** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13.** **Did the Board get a fairness opinion?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Yes, we received a fairness opinion from Centerview Partners LLC.

***Path to Close***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14.** **What approvals are required to complete the transaction, and what is the expected timeline for obtaining them?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The transaction is expected to close in the third quarter of 2026, subject to receipt of customary
regulatory approvals and satisfaction of other conditions to the transaction, including the tender of a majority of the shares of our Class A common stock by our stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The transaction is not subject to any financing condition.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15.** **Are there any anticipated challenges in meeting the conditions to the tender offer?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We're not going to comment on hypotheticals, but we will say that we anticipate a smooth process in
securing the tender of a majority of the shares of our Class A common stock and meeting other conditions to the offer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are confident that stockholders will be pleased with the significant and certain cash value this transaction
delivers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In addition, entities affiliated with Deerfield Partners LP and all directors and officers of Nuvalent have
signed tender and support agreements whereby they agree to tender all of their shares to GSK in connection with the tender offer. The shares subject to the agreements represent a total of approximately 28% of Nuvalent's outstanding shares of
Class A common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16.** **Do you expect any regulatory hurdles?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We do not expect any challenges. If we face challenges, we are well advised and do not anticipate any challenges
that we cannot address.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**17.** **What has the feedback from other stockholders been?** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We speak with our stockholders regularly, however, as a matter of practice we do not comment on the specifics of
those conversations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are confident that stockholders will be pleased with the significant and certain cash value this transaction
delivers.

**Additional Information and Where to Find It** 

The tender offer for the outstanding shares of common stock of Nuvalent has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Nuvalent, nor is it a substitute for the tender offer materials that GSK and its acquisition subsidiaries will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, GSK and its acquisition subsidiaries will file a tender offer statement on Schedule TO, and Nuvalent will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. The tender offer statement on Schedule TO (including an offer to purchase, a related letter of transmittal, and other tender offer documents) and the Solicitation/Recommendation Statement will contain important information. HOLDERS OF SHARES OF NUVALENT ARE URGED TO READ THESE DOCUMENTS WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT NUVALENT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The offer to purchase, the related letter of transmittal, and other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all Nuvalent stockholders at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement also will be made available for free at the SEC's web site at www.sec.gov. Additional copies may be obtained for free on Nuvalent's website, <u>www.nuvalent.com</u>.

**Cautionary Statement Regarding Forward-Looking Statements** 

This communication includes forward-looking statements that are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. All statements, other than statements of historical fact, are generally forward-looking statements, including all statements regarding the intent, belief, or expectations of Nuvalent and its management. These forward-looking statements typically can be identified by words such as "believe," "expect," "estimate," "predict," "target," "potential," "likely," "continue," "ongoing," "could," "should," "intend," "may," "might," "plan," "seek," "anticipate," "project" and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the proposed transaction, similar transactions, prospective performance, future plans, events, expectations, performance, objectives, opportunities, and the outlook for Nuvalent's business; the anticipated timing of potential regulatory approval for Nuvalent's product candidates; the timing of and receipt of filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties; accordingly, investors are cautioned not to place undue reliance on forward-looking statements. Actual results may differ materially due to several factors. Factors that could cause future results to differ materially include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Nuvalent's stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change, or other circumstance that could give rise to the termination of the merger agreement, including circumstances requiring Nuvalent to pay a termination fee pursuant to the merger agreement; the ability of the parties to consummate the proposed transaction on a timely basis or at all; the effects of the transaction (or the announcement or pendency thereof) on relationships with associates, vendors, manufacturers, suppliers, employees (including the risks relating to the ability to retain or hire key personnel), other business partners, or governmental entities or patient groups; transaction costs; the risk that the transaction will divert management's attention from Nuvalent's ongoing business operations or otherwise disrupts Nuvalent's ongoing business operations; changes in Nuvalent's businesses during the period before any closing; certain restrictions during the pendency of the proposed transaction that may impact Nuvalent's ability to pursue certain business opportunities or strategic transactions; risks associated with litigation; risks unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies and clinical trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials; the risk that data from Nuvalent's clinical trials may not be sufficient to support registration and that Nuvalent may be required to conduct one or more additional studies or trials prior to seeking registration of zidesamtinib or neladalkib; risks that Nuvalent may not achieve the goals and milestones set forth in its OnTarget 2026 operating plan; the occurrence of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent's clinical trials, strategy, and future operations, including the ARROS-1, ALKOVE-1, ALKAZAR and HEROEX-1 trials; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and risks related to obtaining, maintaining, and protecting Nuvalent's intellectual property; and other factors as set forth in Nuvalent's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the SEC on May 7, 2026, and other reports filed with the SEC. The forward-looking statements set forth herein speak only as of the date hereof. Nuvalent undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by applicable law.

## Exhibit 99.4

**Exhibit 99.4** 

**Nuvalent Transaction Partner Email** 

Subject: Nuvalent – Our Exciting Next Chapter

Dear ,

I wanted to share some important news about Nuvalent. This morning, we announced that Nuvalent has agreed to be acquired by GSK. You can read more about the announcement in our joint press release: <u>GSK enters agreement to acquire Nuvalent, Inc. \| GSK</u>.

This transaction is a landmark achievement for our company, and we are confident that we have found the right partner in GSK – one of the largest pharmaceutical companies in the world with a proven track record of successfully bringing a wide array of breakthrough therapies to market, including in oncology.

As part of GSK, we expect that their infrastructure and expertise will support successful global development and commercialization of our medicines. This will help realize the full potential of zidesamtinib and neladalkib, enabling timely access for patients who need these treatments. They will also support the continued exploration of the potential across the rest of our pipeline.

In terms of next steps, we expect this transaction to be completed in the third quarter of 2026, subject to satisfaction of closing conditions. Until then, we will continue to operate as an independent company, and it will remain business as usual – including in how we work with you.

We expect to share more details as appropriate in the coming weeks. Thank you for your partnership and continued support for Nuvalent as we enter this exciting new chapter.

Best,

**Additional Information and Where to Find It** 

The tender offer for the outstanding shares of common stock of Nuvalent has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Nuvalent, nor is it a substitute for the tender offer materials that GSK and its acquisition subsidiaries will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, GSK and its acquisition subsidiaries will file a tender offer statement on Schedule TO, and Nuvalent will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. The tender offer statement on Schedule TO (including an offer to purchase, a related letter of transmittal, and other tender offer documents) and the Solicitation/Recommendation Statement will contain important information. HOLDERS OF SHARES OF NUVALENT ARE URGED TO READ THESE DOCUMENTS WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT NUVALENT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The offer to purchase, the related letter of transmittal, and other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all Nuvalent stockholders at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement also will be made available for free at the SEC's web site at www.sec.gov. Additional copies may be obtained for free on Nuvalent's website, www.nuvalent.com.

------

**Cautionary Statement Regarding Forward-Looking Statements** 

This communication includes forward-looking statements that are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. All statements, other than statements of historical fact, are generally forward-looking statements, including all statements regarding the intent, belief, or expectations of Nuvalent and its management. These forward-looking statements typically can be identified by words such as "believe," "expect," "estimate," "predict," "target," "potential," "likely," "continue," "ongoing," "could," "should," "intend," "may," "might," "plan," "seek," "anticipate," "project" and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the proposed transaction, future plans, expectations, and the outlook for Nuvalent's business; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties; accordingly, investors are cautioned not to place undue reliance on forward-looking statements. Actual results may differ materially due to several factors. Factors that could cause future results to differ materially include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Nuvalent's stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change, or other circumstance that could give rise to the termination of the merger agreement, including circumstances requiring Nuvalent to pay a termination fee pursuant to the merger agreement; the ability of the parties to consummate the proposed transaction on a timely basis or at all; the effects of the transaction (or the announcement or pendency thereof) on relationships with associates, vendors, manufacturers, suppliers, employees (including the risks relating to the ability to retain or hire key personnel), other business partners, or governmental entities or patient groups; transaction costs; the risk that the transaction will divert management's attention from Nuvalent's ongoing business operations or otherwise disrupts Nuvalent's ongoing business operations; changes in Nuvalent's businesses during the period before any closing; certain restrictions during the pendency of the proposed transaction that may impact Nuvalent's ability to pursue certain business opportunities or strategic transactions; risks associated with litigation; risks unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies and clinical trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials; the risk that data from Nuvalent's clinical trials may not be sufficient to support registration and that Nuvalent may be required to conduct one or more additional studies or trials prior to seeking registration of zidesamtinib or neladalkib; risks that Nuvalent may not achieve the goals and milestones set forth in its OnTarget 2026 operating plan; the occurrence of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent's clinical trials, strategy, and future operations, including the ARROS-1, ALKOVE-1, ALKAZAR and HEROEX-1 trials; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and risks related to obtaining, maintaining, and protecting Nuvalent's intellectual property; and other factors as set forth in Nuvalent's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the SEC on May 7, 2026, and other reports filed with the SEC. The forward-looking statements set forth herein speak only as of the date hereof. Nuvalent undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by applicable law.